Korro Bio price target raised to $115 from $100 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Korro Bio (KRRO) to $115 from $100 and keeps a Buy rating on the shares. The analyst believes KRRO-110 should be well positioned given its RNA base editing mechanism. The firm thinks Beam Therapeutics’ (BEAM) clinical trial application approval by the UK Medicines and Healthcare Products Regulatory Agency for BEAM-302 reflects the appetite for genomic medicines in AATD-associated lung disease.